Skip to main content

Advertisement

SpringerLink
Log in

Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

To evaluate the efficacy and toxicity of a combination chemotherapy consisting of gemcitabine, carboplatin, and docetaxel (GCD) in patients with advanced urothelial carcinoma (UC) as a phase II trial.

Materials and methods

Patients with metastatic or locally advanced unresectable UC were eligible for this trial. All enrolled patients were considered to be “unfit” for cisplatin-based chemotherapy, or to have methotrexate, vinblastine, doxorubicin, cisplatin (MVAC)-refractory UC. The chemotherapy regimen consisted of gemcitabine 1000 mg/m2 on days 1 and 8, and carboplatin (with a target area under the curve of 5) and docetaxel 70 mg/m2 on day 1; this was repeated every 21 days.

Results

Thirty-five patients were enrolled, with a median age of 68 years. A total of 89 cycles were administered (median, 2 cycles). Major toxicities were Grade 3/4 neutropenia in 28 (80.0%) patients and Grade 3/4 thrombocytopenia in 18 (51.5%). An objective response rate (ORR) was 11 of 21 patients (52.4%), including a complete response in 1 (4.8%). The median overall survival (OS) was 13.1 months (1-year survival rate, 60%) and the median progression-free survival (PFS) was 5.0 months. Among 16 patients who had previously received MVAC, the ORR, the median PFS, the median OS and 1-year survival rate was 56.3%, 5.0 months, 12.6 months and 54%, respectively.

Conclusions

GCD chemotherapy is active and well tolerated as a first- or second-line therapy for patients with advanced UC. Response rate, duration and survival did not differ between those with and without a history of MVAC treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2570

    PubMed  CAS  Google Scholar 

  2. Stadler WM, Kuzel TM, Rahgavan D et al (1997) Metastatic bladder cancer: advances in therapy. Eur J Cancer 33:523–526

    Article  Google Scholar 

  3. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial: Efficacy and patterns of response and relapse. Cancer 64:2448–2458

    Article  PubMed  CAS  Google Scholar 

  4. Kaufman D, Raghavan D, Carducci M et al (2000) Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921–1927

    PubMed  CAS  Google Scholar 

  5. von der Maase VDH, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

  6. MaCafferey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853–1857

    Google Scholar 

  7. Hainsworth JD, Erland JB, Barton JH et al (2003) Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 5:33–38

    Article  PubMed  CAS  Google Scholar 

  8. Hainsworth JD, Spigel DR, Farley C et al (2007) Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer. Cancer 110:2027–2034

    Article  PubMed  CAS  Google Scholar 

  9. Therasse P, Arbucl SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  10. Jekunen AP, Christen RD, Shalinsky DR et al (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cell in vitro. Br J Cancer 69:299–306

    Article  PubMed  CAS  Google Scholar 

  11. Peters GJ, Bergman AM, Ruiz van Haperen VW et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72–79

    PubMed  CAS  Google Scholar 

  12. Dreicer R, Monala J, Roth BJ et al (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18:1058–1061

    PubMed  CAS  Google Scholar 

  13. Zielinski CC, Schnack B, Grbovic M et al (1998) Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 78:370–374

    Article  PubMed  CAS  Google Scholar 

  14. Bellmunt J, de Wit R, Albanell J et al (2001) A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancer. Eur J Cancer 37:2212–2215

    Article  PubMed  CAS  Google Scholar 

  15. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077

    Google Scholar 

  16. Hussain M, Vaishampayan U, Du W et al (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527–2533

    PubMed  CAS  Google Scholar 

  17. Hoshi S, Ohyama C, Ono K et al (2004) Gemcitabine plus carboplatin, and gemcitabine, docetaxel and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen. Int J Clin Oncol 9:125–129

    Article  PubMed  CAS  Google Scholar 

  18. Moore MJ, Winquist EW, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 17:2876–2881

    PubMed  CAS  Google Scholar 

  19. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055

    PubMed  CAS  Google Scholar 

  20. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 7:1066–1073

    Google Scholar 

  21. Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. J Clin Oncol 92:2993–2998

    CAS  Google Scholar 

  22. Lorusso V, Pollera CF, Autimi M et al (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34:1208–1212

    Article  PubMed  CAS  Google Scholar 

  23. Akaza H, Naito S, Usami M et al (2007) Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol 37:201–206

    Article  PubMed  Google Scholar 

  24. Uhm JE, Lim HY, Kim WS et al (2007) Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 9:18–22

    Article  PubMed  CAS  Google Scholar 

  25. Kouno T, Ando M, Yonemori K et al (2007) Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol 52:1115–1122

    Article  PubMed  CAS  Google Scholar 

  26. Soga N, Onishi T, Arima K et al (2007) Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 14:828–832

    Article  PubMed  CAS  Google Scholar 

  27. Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma. Cancer 104:1627–1632

    Article  PubMed  CAS  Google Scholar 

  28. Dreicer R, Manola J, Schneider DJ et al (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium. Cancer 97:2743–2747

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Akita University School of Medicine, Hondo 1-1-1, Akita, Akita, Japan

    Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Mitsuru Saito, Takashi Obara, Kazuyuki Numakura, Shinya Maita, Shigeru Satoh, Norihiko Tsuchiya & Tomonori Habuchi

Authors
  1. Hiroshi Tsuruta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takamitsu Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shintaro Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yohei Horikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuru Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuyuki Numakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinya Maita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shigeru Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Norihiko Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tomonori Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Tsuruta.

About this article

Cite this article

Tsuruta, H., Inoue, T., Narita, S. et al. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. Int J Clin Oncol 16, 533–538 (2011). https://doi.org/10.1007/s10147-011-0224-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0224-4

Keywords

Search

Navigation